Hematology

AML

Questions discussed in this category

Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?

Is there any data on combining the two?

What are your top takeaways in Hematologic Malignancies from ASH 2024?

What is your preferred graft source and conditioning regimen in a patient with Fanconi anemia and AML undergoing stem cell transplant?

Is there a role for non-myeloablative regimens?

1 Answer available

What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

1 Answer available

In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

2 Answers available

Would you treat with AZA + venetoclax to achieve CR2 before proceeding to allogeneic stem cell transplant in a young, fit patient with favorable risk AML who relapsed within a year after 7+3 and HIDAC consolidation?

NGS results are pending

1 Answer available

How do you manage severe cytarabine syndrome in AML patients, manifesting as severe hypotension, fevers, rash, and myalgias?

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

1 Answer available

What is the treatment approach if an AML patient receiving azacitidine/venetoclax is later found to have FLT3 and IDH2 mutations?

1 Answer available

Would you continue ruxolitinib in combination with HMA plus venetoclax in myelofibrosis at the time of transformation to AML?

1 Answer available

For patients receiving outpatient venetoclax/azacitidine who develop profound neutropenia with ANC <200, do you admit for monitoring during the nadir in the absence of fever?

If not, what instructions do you give to patients regarding checking temperature at home/return precautions?

2 Answers available

Is a patient with secondary myeloid sarcoma a candidate for hematopoietic stem cell transplant?

2 Answers available

Would you consider holding treatment with hypomethylating agents and venetoclax in elderly patients diagnosed with AML who achieve CR and are MRD negative?

1 Answer available

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

2 Answers available

What frontline therapy would you offer for a patient who is elderly or unfit for standard induction therapy with both IDH-2 and FLT-3 ITD mutations?

1 Answer available

How would you approach treatment in an otherwise young, fit patient with transformed AML currently in remission with a plan for transplant and was found to have an invasive fungal infection not amenable to resection upon recovery from induction?

Would you consider “bridging” therapy with something like an HMA?

1 Answer available

Would you consider adding Enasidinib to frontline combination therapy with HMA and Venetoclax in a patient with newly diagnosed AML with IDH2 mutation that is >75 or unfit for standard induction therapy?

1 Answer available

What are the options of induction treatment of young AML patients who are on CRRT, continuous renal replacement therapy ?

1 Answer available

For pre-menopausal female patients who present with acute leukemia in need of urgent anti-neoplastic therapy, what is your preferred approach in effort to preserve fertility?

Does acute leukemia sub-type affect your decision?

1 Answer available

How do you manage persistent cytopenias in patients with AML who achieve a complete remission with incomplete count recovery after venetoclax and HMA?

2 Answers available

How much later after starting a hypomethylating agent in an elderly patient with AML being treated in the upfront setting can venetoclax be started?

Can it be added after 2 or 3 cycles of HMA?

1 Answer available

Papers discussed in this category

Medical and pediatric oncology, 1981

The cytosine arabinoside (Ara-C) syndrome.

Fertil. Steril., 2013 Sep 05

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.

Blood, 2019-01-03

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Leukemia, 2019 Oct 18

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.

N. Engl. J. Med.,

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Nature medicine, 2015-02

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.

Clin Infect Dis,

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

American journal of hematology, 2020 Dec 08

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.

Blood cancer journal, 2023 Oct 11

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.

Bone marrow transplantation, 2020 Dec 07

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Jul 16

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).

Archives of drug information, 2008-12

A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.

Bone marrow transplantation, 2003 Jul

G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003 Dec 22

Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Leukemia, 2005 Apr

Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation.

Transplantation and cellular therapy, 2021 Oct 02

Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.

Cancer, 2023 Jun 24

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

The Lancet. Oncology, 2014-08

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

The New England journal of medicine, 2017-08-03

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Nature genetics, 2016-12

The genomic landscape of core-binding factor acute myeloid leukemias.

Haematologica, 2022 Apr 01

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.

EJHaem, 2024 Aug

Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia.

Blood, 2022 Sep 22

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.

Blood cancer journal, 2022 Apr 07

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".

Lancet (London, England), 2023 Apr 25

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.

British journal of haematology, 2024 Apr 09

Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.

Hematology

AML

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematology